Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Fennec Pharmaceuticals. The associated price target remains the same with $13.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ram Selvaraju has given his Buy rating due to a combination of factors tied to PEDMARK’s commercial and clinical trajectory. He highlights the initiation of a real‑world outcomes study at Tampa General Hospital, which should generate practice‑based data supporting broader use of PEDMARK beyond its current pediatric approval and NCCN‑backed adolescent and young adult setting, reinforcing the product’s long‑term adoption potential.
He also underscores upside from planned registration efforts in Japan, which are not yet reflected in his model, as well as an improving financial profile with an expectation that Fennec is now profitable and should remain so. Based on a risk‑adjusted NPV of PEDMARK plus pipeline combination products and the company’s cash position and share count, he derives a total equity value that supports a $13 per‑share 12‑month target, while acknowledging regulatory, commercial uptake, and partnership execution risks.